

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
3 January 2002 (03.01.2002)

PCT

(10) International Publication Number
WO 02/00164 A2

- (51) International Patent Classification⁷: A61K
LV, MA, MG, MN, MX, NO, NZ, PL, RO, SG, SK, TT, UA, US, UZ, VN, YU, ZA, ZW.
- (21) International Application Number: PCT/IB01/01133
- (22) International Filing Date: 26 June 2001 (26.06.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 591/Mum/2000 26 June 2000 (26.06.2000) IN
Declaration under Rule 4.17:
of inventorship (Rule 4.17(iv)) for US only
- (71) Applicant: KHAMAR, Bakesh, Mafatali [IN/IN]; 201 Ashadha, Vasundhara Colony, Gulbai Tekra, Ellisbridge, Ahmedabad 380 006, Gujarat (IN).
Published:
— without international search report and to be republished upon receipt of that report
- (81) Designated States (national): AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EC, EE, GE, GD, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT;
For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CHEMOSENSITIZER

WO 02/00164 A2

(57) Abstract: Chemotherapeutic agents are used to treat infections caused by bacteria, virus, protozoa, parasites, and various malignant diseases like cancer. The major problem associated with use of chemotherapeutic agents is resistance to chemotherapeutic agents. Mechanisms underlying resistance to chemotherapeutic agents include inactivation/modification of antibiotic (beta-lactams, chloramphenicol), insensitive target site (beta-lactams, glycopeptides, macrolides, tetracyclines), decreased drug accumulation in the form of enhanced efflux (tetracyclines, chloroquine, macrolides, anticancer drugs), by-pass of antibiotic sensitive step (methicillin, sulphonamides) etc. The common mechanisms underlying drug resistance is to restrict concentration of drug at the site of action usually intracellular. This can be in the form of restricting the entry of the drug into the cell by various mechanisms including altered cell wall permeability. It can also be in the form of removing the drug from site of action e.g. intracellular so that therapeutic concentration are not achieved. The drugs restoring sensitivity of chemotherapeutic agents are broadly known as chemosensitizers. Compounds belonging to a group of R-1-3-benzodioxole are found to be chemosensitizer as per the present invention. Piperine is one such compound belonging to a group of R-1-3-benzodioxole are found to be chemosensitizer as per the present invention. Piperine is one such compound belonging to R-1-3 benzodioxole group. It is found to reverse resistance to chemotherapeutic agents like rifampicin at dose which is easily achievable after oral ingestion of the drug.

THE PATENTS ACT, 1970
THE COMPLETE SPECIFICATION

1. CHEMOSENSITIZER.
2. Dr. Bakulesh Mafatlal Khamar, residing at 201 "Ashadha", Vasundhara Colony, Gulbai Tekra, Ellisbridge, Ahmedabad 380 006, Gujarat, India, Nationality: Indian
3. The following specification particularly describes the nature of this invention and the manner in which it is to be performed.

FIELD OF INVENTION

The objective of the present invention is to provide a chemosensitizer for therapeutic use.

The further objective of the present invention is to provide a chemosensitizer, the dose of which, as chemosensitizer is achievable.

BACKGROUND OF THE INVENTION

Chemotherapeutic agents are used to treat infections caused by bacteria, virus, protozoa, parasites, etc. They are also used in management of various malignant diseases (cancer). The major problem associated with use of chemotherapeutic agents is resistance to chemotherapeutic agents.

Mechanisms underlying resistance to chemotherapeutic agents include inactivation/modification of antibiotic (beta-lactams, chloramphenicol), insensitive target site (beta-lactams, glycopeptides, macrolides, tetracyclines), decreased drug accumulation in the form of enhanced efflux (tetracyclines, chloroquine, macrolides, anticancer drugs), by-pass of antibiotic sensitive step (methicillin, sulphonamides) etc. The common mechanisms underlying drug resistance is to restrict concentration of drug at the site of action usually intracellular. This can be in the form of restricting the entry of the drug into the cell by various mechanisms including altered cell wall permeability. It can also be in the form of removing the drug from site of action e.g. intracellular so that therapeutic concentration are not achieved.

This is largely done by throwing out intracellular drug at a rate faster than usual so that balance of drug concentration is disturbed resulting into lower intracellular concentration. This is done through the mechanism which is known as efflux pump. The other mechanism of decreasing therapeutic concentration of a drug include metabolism/alteration of drug to inactive compound e.g. secretion of enzymes like penicillinase or β -lactamase which destroys penicillins or β -lactam antibiotics.

Attempts have been made and efforts are on to counteract this acquired drug resistance. One way is to improve chemotherapeutic agents e.g. penicillin's resistant penicillin like Cloxacillin, dicloxacillin, methicillin, flucloxacillin etc. or β -lactamase resistance antibiotics like temocillin in a group of penicillin or advanced cephalosporins, monobactams etc.

The other way is to find out drugs to overcome resistance for use along with chemotherapeutic agents e.g. β -lactamase inhibitors like clavulanic acid, salbactam, tazobactam to be used along with antibiotics like ampicillin, amoxycillin, ticarcillin etc.

However, this approach has been successful in situations wherein β -lactamase enzyme has been the problem.

The present situation is faced with new mechanism of resistance, like enhancement of efflux responsible for multi-drug resistance. This was initially seen with tetracycline antibiotics, but now is extended to many antibiotics like ciprofloxacin, norfloxacin, chloroquine and also has extended to many anticancer therapies (shown in the list below) which is now the major mechanism of resistance.

To overcome this efflux, attempts have been made by use of compounds called chemosensitizers. For example, calcium channel blocker, verapamil has been used to reverse chloroquine resistance in *Plasmodium falciparum*.

Likewise, modified tetracyclines has been used as chemosensitizers to overcome efflux mediated drug resistance.

In case of anticancer therapies, several compounds have been identified that enhanced drug's accumulation inside the cell like verapamil, amiodarone, steroids, cyclosporins, phenothiazines and other compounds as shown in the list below.

The drugs to be used along with chemotherapeutic agents (Table 1) for restoring sensitivity to chemotherapeutic agents are broadly known as chemosensitizers (Table 2). Many drugs used for various therapeutic effect are found to be good for this purpose e.g. Verapamil, Reserpine, Cyclosporin.

Some of the chemotherapeutic agents like rifampicin can work as a chemotherapeutic agent as well as chemosensitizer.

Table 1:

Chemotherapeutic Agents		
Doxorubicin	Mitoxantrone	Ciprofloxacin
Daunorubicin	Bleomycin	Norfloxacin
Vincristine	Rifampicin	Fluconazole
Vinblastine	Isoniazid	Itraconazole
Paclitaxel	Rifabutin	Ketoconazole
Carboplatin	Chloroquine	Clarithromycin
Etoposide	Tobramycin	Azithromycin
Taxotrene	Cloxacillin	Erythromycin
Topotecan	Dicloxacillin	Tetracycline
Adriamycin	Clavulanic acid	Carbenicillin
Cisplatin	Salbactam	Cefodizime
5-Fluorouracil	Tazobactam	Quinine

Table 2:

Chemosensitizers		
Carbonyl cyanide m-		Trans-(E)- Flupentixol
chlorophenylhydrazine		
Reserpine		Malagashanine
Verapamil		GF-120918
Cyclosporin A		HD-37
Omeprazole		L-Canavanine
Orthovondate		PSC-833
Trifluoperazine		Biricodar (VX-710)
5-methoxyhydnocarbin (5'-MHC)		GG 918
Valspodar		

However, the main problem associated with their use is higher therapeutic dose. It is not possible to administer known chemosensitizers in an amount necessary to obtain therapeutic levels required for chemosensitizing effect. Because of these they have not found wide spread applications. The search is going on to find out newer drugs for these purposes which can be used safely in therapeutic dose.

REFERENCES:

1. Chiba P et al. Substituted 4- acylpyrazoles and 4-acylpyrazolones: synthesis and multidrug resistance modulating activity.
J Med Chem 1998; 41: 4001-4011.
2. Norman BH. Inhibitors of MRP_1 mediated multi-drug resistance.
Drugs of the Future 1998; 23(9): 1001-13.
3. Nikadio H. Antibiotic resistance caused by gram negative multi-drug pump efflux pumps.
Clin Infect Dis 1998; 27 Suppl 1: S32-41.
4. Pechere JC et al. Antibiotic efflux, a mechanism of multiple resistance in *Pseudomonas aeruginosa*.
Bull Acad Natl Med 1998; 182(3): 599-612.
5. Roberts MC. Tetracycline resistance determinants: mechanisms of action, regulation of expression, genetic mobility and distribution.
FEMS Microbiol Rev 1996; 19(1): 1-24.
6. Schnappinger D and Hillen W.
Tetracyclines: antibiotic action, uptake and resistance mechanisms.
Arch Microbiol 1996; 165(6): 359-69.
7. Sum PE et al. Recent developments in tetracycline antibiotics.
Curr Pharm Des 1998; 4(2): 119-32.
8. Nikaido H. Multiple antibiotic resistance and efflux.
Curr Opin Microbiol 1998; 1(5): 516-23.

9. Piddock LJ et al. Accumulation of rifampicin my *Mycobacterium aurum*, *Mycobacterium smegmatis* and *Mycobacterium tuberculosis*. *J Antimicrob Chemother* 2000; 45(2): 159-65.
10. Aeschlimann JR et al. The effects of NorA inhibition on the activities of levofloxacin, ciprofloxacin, and norfloxacin against two genetically related strains of *Staphylococcus aureus* in an in vitro infection model. *J Antimicrob Chemother* 1999; 44(3): 343-9.
11. Choudhuri BS et al. Isoniazid accumulation in *Mycobacterium smegmatis* id mediated by proton motive force driven and ATP dependent extrusion systems. *Biochem Biophys Res Commun* 1999; 256(3): 682-4.
12. De Flora S et al. Modulation of the potency of promutagens and direct acting mutagens in bacteria by inhibitors of the multidrug resistance mechanism. *Mutagenesis* 1997; 12(6): 431-5.
13. Theis JG et al. Assessment of systemic toxicity in children receiving chemotherapy with cyclosporine for sarcoma. *Med Paediatr Oncol* 2000; 34(4): 242-9.
14. Hafkemeyer P et al. Chemoprotection of haematopoietic cells by a mutant P-glycoprotein resistant to a potent chemosensitizer of multi-drug resistant cancers. *Hum Gene Ther* 2000; 11(4): 555-65.
15. Rafatro H et al. Reversal activity of the naturally occurring chemosensitizer malagashanine in *Plasmodium malaria*. *Biochem Pharmacol* 2000; 59(9): 1053-61.
16. Yanagisawa T et al. Biricodar (VX-710): an effective chemosensitizer in neuroblastoma. *Br J Cancer* 1999; 80(8): 1190-6.
17. Papadopolou MV et al. NLCQ-1, a novel hypoxic cytotoxin: potentiation of melphalan, cisDDPO and cyclophosphamide in vivo. *Int J Radiat Oncol Biol Phys* 1998; 42(4): 775-9.

18. Sharom FJ. The P-Glycoprotein efflux pump: How does it transports drugs?
J Memb Biol 1997; 160(3): 161-75.
19. Schmitz FJ et al. The effect of reserpine, an inhibitor of multidrug efflux pumps, on the invitro activities of ciprofloxacin, sparfoxacin and moxifloxacin against clinical isolates of Staphylococcus aureus.
J Antimicrob Chemother 1998; 42(6): 807-10.
20. Markham PN. Inhibition of the emergence of ciprofloxacin resistance in Streptococcus pneumoniae by the multidrug efflux inhibitor reserpine.
Antimicrob Ag Chemother 1999; 43(4): 988-9.
21. Nakanishi N et al. Mechanisms of clinical resistance to fluoroquinolones in Staphylococcus aureus.
Antimicrob Ag Chemother 1991; 35(12): 2562-7.
22. Nelson ML. Inhibition of Tetracycline efflux antiport protein by 13-Thio-Substitute, 5-hydroxy-6-deoxytetracyclines.
J Med Chem 1993; 36: 37-7.
23. Courtols A et al. Inhibition of multi-drug resistance-associated protein (MRP) activity by rifampicin in human multi-drug resistant lung tumor cells.
Cancer Lett 1999; 139(1): 97-104.
24. Piddock LJ et al. Accumulation of rifampicin my Mycobacterium aurum, Mycobacterium smegmatis and Mycobacterium tuberculosis.
Antimicrob Ag Chemother 2000; 45(2): 159-65.

SUMMARY OF THE INVENTION


The present invention provides a chemosensitizer for therapeutic use, the dose of which as chemosensitizer is achievable. The chemosensitizer as per the present invention belongs to R-1-3 benzodioxoles.

Piperine is a compound belonging to R-1-3 benzodioxoles. Strains of M. tuberculosis growing in presence of 40 mcg/ml of rifampicin are inhibited at various concentrations of piperine, the concentration of which is not more than 5 mcg/ml.

Similarly in case of chloroquine-resistant *P. falciparum* strains, amount of piperine is dependent on level of resistance and amount of chloroquine.

DESCRIPTION OF THE INVENTION

According to the present invention it is observed that R-1-3 Benzodioxole compounds with structural formula



are chemosensitizers.

The amount of chemosensitizer required is dependent on the compound, chemotherapeutic agent and level of resistance.


The following examples provide proof of such compounds working as chemosensitizer.

EXAMPLE 1


Rifampicin is a chemotherapeutic agent useful in the management of tuberculosis. Resistance to rifampicin is a major health problem.

A strain of mycobacterium is considered resistant if it grows in presence of rifampicin 40 mcg/ml.

Piperine is a compound belonging to a class of compound which can be grouped as R-1-3 benzodioxole, where in, R is



Piperine with structural formula



is found to reverse resistance to rifampicin. The amount of piperine required for this action does not have any effect on *Mycobacterium tuberculosis*.

The table below gives results of such study against nine different such strains. It is clear that all strains growing in vitro in presence of 40 mcg/ml of rifampicin are inhibited at various concentration of piperine. The concentration of piperine required for this purpose is not more than 5 mcg/ml.

RIFA resistant strain	Control RIFA 40 mcg/ml	RIFA 8 mcg/ml			RIFA 40 mcg/ml		
		Piperine mcg/ml			Piperine mcg/ml		
		1	2	5	1	2	5
1	+++	++	NG	NG	NG	NG	NG
2	+++	++	NG	NG	NG	NG	NG
3	+++	++	+	NG	+	NG	NG
4	+++	++	NG	NG	+	NG	NG
5	+++	+	NG	NG	NG	NG	NG
6	+++	NG	NG	NG	NG	NG	NG
7	+++	++	+	NG	+	NG	NG
8	+++	++	NG	NG	NG	NG	NG
9	+++	+	+	NG	+	NG	NG

EXAMPLE 2:

Chloroquine is used in the management of malaria. One of the organism, *Plasmodium falciparum* has acquired resistance to chloroquine. This is the major cause of morbidity and mortality caused by malaria.

The table below shows how piperine at different concentrations overcomes *P. falciparum* resistance to chloroquine. The figures in each cell shows % inhibition of *P. falciparum*. It clearly shows that % inhibition for a resistant strain of *P. falciparum* can be improved by addition of piperine. Inhibition can be increased by increasing the dose of either compound.

Concentration of Chloroquine (p.mols)	CHLOROQUINE + PIPERINE						
	CQ	20 mg	60 mg	100mg	200 mg	600 mg	1000mg
1	09.6	6.3	79.0	100	100	100	100
2	27.7	17.7	90.0	100	100	100	100
4	33.7	22.8	93.8	100	100	100	100
8	57.8	65.8	100	100	100	100	100
16	83.1	100	100	100	100	100	100
32	95.2	100	100	100	100	100	100
64	100	100	100	100	100	100	100

The amount of piperine required is dependent on level of resistance and amount of chemotherapeutic agent.

Piperine was evaluated for its bioavailability and toxicity in animals.

The results of the pharmacokinetic study in rat (Figure 1) shows that compound is absorbed from intestinal tract when given orally. It also indicates that compound has a long half-life.

The toxicological study also reveals that piperine is non toxic.


Pharmacokinetic study in humans (table below and Figure 2) also reveal that piperine is absorbed from gastrointestinal tract, and adequate therapeutic concentration can be achieved.

Dose (mg)	Time in hours										
	0	1	2	3	4	6	8	12	24	30	36
100	0	0.168	1.403	1.95	1.691	1.633	1.534	1.457	0.688	0.428	-
		±	±	±	±	±	±	±	±	±	
		0.099	0.278	0.434	0.314	0.227	0.225	0.342	0.186	0.083	
250	0	0.684	2.322	3.754	3.768	3.797	3.337	2.935	1.873	1.40	0.913
		±	±	±	±	±	±	±	±	±	±
		0.439	0.65	1.108	0.873	0.919	0.558	0.526	0.348	0.281	0.189
500	0	1.292	4.243	7.406	9.481	7.717	7.494	6.813	5.393	4.381	3.149
		±	±	±	±	±	±	±	±	±	±
		0.48	1.027	1.284	1.635	1.024	0.982	0.99	0.988	0.707	0.72



Thus, according to the present invention is provided R-1-3 benzodioxole compounds useful as chemosensitizers. These compounds can be useful in therapy as it is possible to achieve therapeutic levels in plasma.

I claim:

1. R-1-3 Benzodioxoles as a chemosensitizer with a structural formula



2. A chemosensitizer as claimed in claim 1 can be piperine wherein R is



3. A chemosensitizer as claimed in claim 1 to 2 is useful in overcoming resistance of chemotherapeutic agents.
4. Chemotherapeutic agent as claimed in claim 3 can be rifampicin.
5. Chemotherapeutic agents as claimed in claim 3 can be antimetabolites.
6. Antimetabolites as claimed in claim 5 can be selected from group comprising Doxorubicin, Daunorubicin, Vincristine, Vinblastine, Paclitaxel, Carboplatin, Etoposide, Taxotrene, Topotecan, Adriamycin, Cisplatin, 5-Fluorouracil, Mitoxantrone, Bleomycin and the like.
7. Chemotherapeutic agent as claimed in claim 3 can be chloroquine.

FIGURE 1: PHARMACOKINETIC STUDY IN RAT




FIGURE 2: PLASMA CONCENTRATION -TIME PROFILE
AFTER ORAL ADMINISTRATION IN HUMAN VOLUNTEERS

